JAMA Intern Med:美国个人肺癌筛查项目医学告知透明度研究

2020-04-14 MedSci原创 MedSci原创

美国肺癌筛查项目网站中,公开描述筛查的潜在益处和危害方面存在不平衡。重要的危害,如过度诊断,通常被忽视

美国预防服务特别工作组建议,肺癌高危人群在进行肺癌筛查之前,应考虑其利弊。为此医疗中心建立了肺癌筛查项目专业网站,但这一措施是否能提高潜在筛查者对于肺癌筛查的认知程度目前知之甚少。
 
研究人员从美国放射学院肺癌筛查指定中心中,随机抽取了162个学术医疗中心(n=81)和国家匹配的社区医疗中心(n=81),对肺癌筛查项目网站内容进行横断面分析。研究的主要终点为网站介绍与筛选相关的好处和危害,好处定义为与肺癌死亡率潜在降低相关的任何描述。危害包括假阳性、假阴性、过度诊断、辐射暴露和偶然发现。次要结果是网站建议的改进措施。
 
总的来说,162个肺癌筛查项目网站描述潜在益处的频率高于描述潜在危害的频率(159革[98%] vs 78个[48%)。假阳性结果是最常见的潜在危害(72个[44%])。社区中心比学术中心相比,报告任何潜在伤害(32[40%] vs 46[57%],P=0.03),辐射潜在伤害(20[25%] vs 35[43%],P=0.01)以及过度诊断(0% vs 11[14%],P=0.01)的比例较低。119个网站(73%)没有明确告知个人考虑筛查的潜在益处和危害,社区中心告知潜在益处和危害的比例较低(15[19%] vs 28[35%],P?=?0.02)。大多数机构(157[97%])列出了筛查的后续步骤,但很少机构(35[22%])建议个人与医疗专业人员讨论益处和危害。
 
研究认为,美国肺癌筛查项目网站中,公开描述筛查的潜在益处和危害方面存在不平衡。重要的危害,如过度诊断,通常被忽视。
 
原始出处:
 
Stephen D. Clark et al. Assessment of Lung Cancer Screening Program Websites. JAMA Intern Med. April 13,2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670420, encodeId=4aff16e042012, content=<a href='/topic/show?id=1a88948135e' target=_blank style='color:#2F92EE;'>#透明度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94813, encryptionId=1a88948135e, topicName=透明度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8f926667578, createdName=oliver178, createdTime=Sat Sep 26 03:39:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803821, encodeId=dd3d1803821d1, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Mon Sep 07 00:39:57 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610431, encodeId=b5031610431e6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 10:39:57 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036037, encodeId=073c103603e17, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Apr 14 22:39:57 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1670420, encodeId=4aff16e042012, content=<a href='/topic/show?id=1a88948135e' target=_blank style='color:#2F92EE;'>#透明度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94813, encryptionId=1a88948135e, topicName=透明度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8f926667578, createdName=oliver178, createdTime=Sat Sep 26 03:39:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803821, encodeId=dd3d1803821d1, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Mon Sep 07 00:39:57 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610431, encodeId=b5031610431e6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 10:39:57 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036037, encodeId=073c103603e17, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Apr 14 22:39:57 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1670420, encodeId=4aff16e042012, content=<a href='/topic/show?id=1a88948135e' target=_blank style='color:#2F92EE;'>#透明度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94813, encryptionId=1a88948135e, topicName=透明度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8f926667578, createdName=oliver178, createdTime=Sat Sep 26 03:39:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803821, encodeId=dd3d1803821d1, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Mon Sep 07 00:39:57 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610431, encodeId=b5031610431e6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 10:39:57 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036037, encodeId=073c103603e17, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Apr 14 22:39:57 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-04-16 智慧医人
  4. [GetPortalCommentsPageByObjectIdResponse(id=1670420, encodeId=4aff16e042012, content=<a href='/topic/show?id=1a88948135e' target=_blank style='color:#2F92EE;'>#透明度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94813, encryptionId=1a88948135e, topicName=透明度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8f926667578, createdName=oliver178, createdTime=Sat Sep 26 03:39:57 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803821, encodeId=dd3d1803821d1, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Mon Sep 07 00:39:57 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610431, encodeId=b5031610431e6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 10:39:57 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036037, encodeId=073c103603e17, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Apr 14 22:39:57 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-04-14 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Chest:有偿服务医疗保险受益人的肺癌筛查利用率

研究发现自医疗保险开始实施报销政策以来,LCS利用率呈稳定增长。

2020 ESR/ERS声明文件:肺癌的筛查

2020年2月,欧洲放射学会(ESR)联合欧洲呼吸学会(ERS)共同发布了肺癌的筛查声明,自2015年上述两学会发布肺癌筛查白皮书以来,有许多新的发现已经发表,相关讨论也逐渐增加。这一最新的专家意见代表了对LCS试验证据的叙述性、非系统性的审查,以及对LCS当前实践的描述。

2020版NCCN肺癌筛查指南解读

全球肺癌发病率不断升高,其 5 年生存率仅为 19%,主要原因是多数患者在发现时已处于进展期,因此很有必要开展肺癌筛查工作。世界各地开展肺癌筛查工作的方法和标准各有不同,美国国立综合癌症网络(NCCN)自 2011 年开始制定和公布肺癌筛查的指南,至今每年至少作一次版本更新。指南内容主要包括:(1)具体描述肺癌发生的高危因素;(2)推荐具有高危因素的患者进行选择性肺癌筛查;(3)对于发现肺部结节或

Thorax:NELSON CT肺癌筛查研究随机轮次中持续存在的新结节

LDCT肺癌筛查中超过一半的新发低中危实性结节会消退。随访中,与体积阈值相结合的生长评估可被用于风险分层。

2018 ACR适宜性标准:肺癌筛查

2018年11月,美国放射学会(ACR)发布了肺癌筛查的影像学检查标准建议,肺癌仍是癌症死亡的主要原因,本文主要针对肺癌筛查的影像学检查提供指导建议,涉及低剂量CT筛查和肺癌筛查的年龄以及人群等。

肺癌筛查+戒烟,能减少一半以上肺癌死亡率!

早在2013年,美国预防服务工作组就建议: